Oncosil Medical Ltd (ASX:OSL)
OncoSil Medical Limited is an Australia-based biotechnology company. The Company is focused on unresectable locally advanced pancreatic cancer (LAPC). The Company's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. It enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.